Barclays raised the firm’s price target on Encompass Health to $108 from $101 and keeps an Overweight rating on the shares post the Q1 report. The company reported strong discharge growth, solid pricing and well controlled costs, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health Enhances Investor Insights with Adjusted Financials
- Encompass Health reports results for first quarter 2024
- Encompass Health (EHC) Q1 Earnings Cheat Sheet
- Encompass Health to build 50-bed rehabilitation hospital in San Antonio
- Encompass Health price target raised to $101 from $95 at Barclays